Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Aurelie Catteau"'
Autor:
Frank A. Sinicrope, Qian Shi, Aurelie Catteau, Graham M. Poage, Tyler J. Zemla, Bernhard Mlecnik, Al B. Benson, Sharlene Gill, Richard M. Goldberg, Morton S. Kahlenberg, Suresh G. Nair, Anthony F. Shields, Thomas C. Smyrk, Jerome Galon, Steven R. Alberts
Publikováno v:
JCO Precision Oncology.
PURPOSE The recommended duration of adjuvant fluoropyrimidine and oxaliplatin chemotherapy for patients with stage III colon cancer is based on tumor classification into clinically low-risk (T1-3 N1) and high-risk (T4 or N2) groups. We determined whe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed77c7c833d4abdc93a928c901640b00
https://doi.org/10.1200/po.22.00010
https://doi.org/10.1200/po.22.00010
Autor:
Isabelle Boquet, Alboukadel Kassambara, Alfred Lui, Alicia Tanner, Marie Latil, Yoann Lovera, Fanny Arnoux, Fabienne Hermitte, Jérôme Galon, Aurelie Catteau
Publikováno v:
Cancers; Volume 14; Issue 5; Pages: 1170
Adjunction of immune response into the TNM classification system improves the prediction of colon cancer (CC) prognosis. However, immune response measurements have not been used as robust biomarkers of pathology in clinical practice until the introdu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11b30f7efa12a4007f78ad7de4c48b12
https://pubmed.ncbi.nlm.nih.gov/35267475
https://pubmed.ncbi.nlm.nih.gov/35267475
Autor:
Dewi Vernerey, Aurelie Catteau, Afsaneh Barzi, Graham M. Poage, Efrat Dotan, Anup Kasi, Manju George
Publikováno v:
Cancers
Volume 13
Issue 21
Cancers, Vol 13, Iss 5467, p 5467 (2021)
Volume 13
Issue 21
Cancers, Vol 13, Iss 5467, p 5467 (2021)
Simple Summary Selection of appropriate stage II colon cancer patients for adjuvant chemotherapy (AC) is controversial. A novel immune response classifier has previously been validated to refine patient selection, but its impact on oncologist treatme
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35e2405ce3da867d4d7d30d57bd7ecb3
Autor:
Jerome Galon, Frederic Bibeau, Laurent Greillier, Jean David Fumet, Alis Ilie, Florence Monville, Caroline Laugé, Aurelie Catteau, Isabelle Boquet, Amine Majdi, Youssef Oulkhouir, Nicolas Brandone, Julien Adam, Thomas Sbarrato, Alboukadel Kassambara, Jacques Fieschi, Stephane Garcia, Anne Laure Lepage, Pascale Tomasini, François Ghiringhelli
Publikováno v:
Journal of Clinical Oncology. 40:2509-2509
2509 Background: Anti-PD1 and PD-L1 antibodies (mAb) are immune checkpoint inhibitors (ICIs) to treat patients with metastatic non–small cell lung cancer (NSCLC). Unfortunately, only a handful of patients respond to ICIs. Methods: A cohort of patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4b1c06ee70fd4dacfc791ca84b5c27b1
https://doi.org/10.1200/jco.2022.40.16_suppl.2509
https://doi.org/10.1200/jco.2022.40.16_suppl.2509
Autor:
Roubini Zakopoulou, Aristotelis Bamias, Marie Auvray, Philippe Camparo, Xavier Barthere, Mostefa Bennamoun, Daniela Bruni, Pierre Colin, Isabelle Boquet, Jérôme Galon, Gabriela Bindea, Elise F. Nassif, François Audenet, Virginie Verkarre, Bernhard Mlecnik, Alexandre Colau, Bruno d’Acremont, Aurelie Catteau, Stéphane Oudard, Marine Martel, Marine Lefevre, Arnaud Mejean, Eva Comperat, Aurelie Fugon, Constance Thibault
Publikováno v:
Cancers
Cancers, MDPI, 2021, 13 (3), pp.494. ⟨10.3390/cancers13030494⟩
Volume 13
Issue 3
Cancers, Vol 13, Iss 494, p 494 (2021)
Cancers, MDPI, 2021, 13 (3), pp.494. ⟨10.3390/cancers13030494⟩
Volume 13
Issue 3
Cancers, Vol 13, Iss 494, p 494 (2021)
(1) Background&mdash
The five-year overall survival (OS) of muscle-invasive bladder cancer (MIBC) with neoadjuvant chemotherapy and cystectomy is around 50%. There is no validated biomarker to guide the treatment decision. We investigated whethe
The five-year overall survival (OS) of muscle-invasive bladder cancer (MIBC) with neoadjuvant chemotherapy and cystectomy is around 50%. There is no validated biomarker to guide the treatment decision. We investigated whethe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65fa3039bd201fa65a8e309e9d69ea78
https://hal.sorbonne-universite.fr/hal-03154109/document
https://hal.sorbonne-universite.fr/hal-03154109/document
Autor:
Julien Taieb, Jean-François Emile, Pierre Laurent-Puig, Magali Svrcek, Dewi Vernerey, Amos Kirilovsky, R. Ben Jannet, Alex Duval, Thierry André, Roger Faroux, Julie Henriques, Jaafar Bennouna, Florence Marliot, Laurent Mineur, Jérôme Galon, Christophe Borg, Franck Pagès, Aurelie Catteau, Jérôme Desramé, Christophe Louvet, Fabienne Hermitte
Publikováno v:
Annals of Oncology
unknow
Annals of Oncology, Elsevier, 2020, 31 (7), pp.921-929. ⟨10.1016/j.annonc.2020.03.310⟩
unknow
Annals of Oncology, Elsevier, 2020, 31 (7), pp.921-929. ⟨10.1016/j.annonc.2020.03.310⟩
International audience; Background: The Immunoscore (IS), which prognostically classifies stage I–III colon cancer (CC) patients, was evaluated in the International Duration Evaluation of Adjuvant Therapy (IDEA) France cohort study investigating 3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e47607abd6c5cac52867c74fbbd5fa59
https://hal.archives-ouvertes.fr/hal-02927418/document
https://hal.archives-ouvertes.fr/hal-02927418/document
Autor:
David Church, Owen Sansom, Noori Maka, Joanne Edwards, Karin Oien, Timothy Iveson, Mark P. Saunders, Ioannis Boukovinas, Ippokratis Messaritakis, Eleni Moustou, Maria Chondrozoumaki, Vassilis Georgoulias, Alboukadel Kassambara, Aurelie Catteau, Jerome Galon, Laura Dempsey, Jennifer Hay, Caroline Kelly, Ioannis Sougklakos, Andrea Harkin
Publikováno v:
Journal of Clinical Oncology. 40:196-196
196 Background: The ESMO clinical practice guidelines recommend consideration of Immunoscore (IS) for risk assessment of early colon cancer patients. IS clinical performance was assessed in the SCOT and IDEA-HORG trials evaluating 3 vs. 6 months (3m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ea42c7b62eed8a84aeb71742c4a6ec45
https://doi.org/10.1200/jco.2022.40.4_suppl.196
https://doi.org/10.1200/jco.2022.40.4_suppl.196
Autor:
Fulong Wang, Shixun Lu, Di Cao, Juanjuan Qian, Cong Li, Rongxin Zhang, Feng Wang, Miaoqing Wu, Yifan Liu, Zhizhong Pan, Xiaojun Wu, Zhenhai Lu, Peirong Ding, Liren Li, Junzhong Lin, Aurélie Catteau, Jérôme Galon, Gong Chen
Publikováno v:
OncoImmunology, Vol 12, Iss 1 (2023)
ABSTRACTThis study aimed to validate the prognostic value of Immunoscore (IS) in stage II colorectal cancer (CRC), and explore the roles of IS and circulating tumor DNA (ctDNA) in the adjuvant treatment for early-stage CRC. Resected tumor samples fro
Externí odkaz:
https://doaj.org/article/89b95f1a4dbf4a6e976c2cbd1aeac50d
Publikováno v:
Journal of Clinical Oncology. 38:295-295
295 Background: Approximately 25% of patients with colon cancer are diagnosed at stage II. Recommendations for adjuvant chemotherapy and follow-up for these patients are risk-based, however the benefit of therapy is not supported by consistent, robus
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::225b18774c5899ed3e455196077998bf
https://doi.org/10.1200/jco.2020.38.29_suppl.295
https://doi.org/10.1200/jco.2020.38.29_suppl.295
Autor:
C. Louvet, Christophe Borg, Jaafar Bennouna, Laurent Mineur, F. Marliot, Pierre Laurent-Puig, Franck Pages, J-F. Emile, Alex Duval, Amos Kirilovsky, Julie Henriques, Roger Faroux, Magali Svrcek, Jérôme Galon, Dewi Vernerey, R. Ben Jannet, Aurelie Catteau, Fabienne Hermitte, Julien Taieb, Jérôme Desramé, Thierry André
Publikováno v:
Annals of Oncology. 31:1276
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7b8c9cb5fb09733b2cedb8d874fcefae
https://doi.org/10.1016/j.annonc.2020.06.013
https://doi.org/10.1016/j.annonc.2020.06.013